OT
Omori, T.
4 yayın · 248 atıf · 2023–2025
Yayın
4
Atıf
248
Yıllar
2
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
|
2025 | Meeting Abstract | 4 |
|
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
|
2025 | Article | 161 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 11 |
|
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
|
2023 | Meeting Abstract | 72 |